Novo Nordisk A/S Class B OverviewNovo Nordisk A/S Class B Research & Development
Research & Development expenses for NONOF.
Quarterly R&D Expenses
$10.28B
↓ 0.23% YoY
As of Mar 31, 2026
Annual R&D Expenses (TTM)
$51.98B
↑ 4.46% YoY
Trailing 12 months ending Mar 31, 2026